The aim of this work was to determine whether intramuscular administration of injectable fasciolicide fosfatriclaben, in a single dose at 6 mg/kg in dairy cattle, produces adverse reactions manifested through blood biochemical and histopathological profiles, especially in organs involved in drug metabolism. For the study, nine out of ten Holstein-Freisian dairy cows were treated, leaving one cow untreated as a control. On days 0, 7, 14, and 28 post-treatment, liver, kidney, and injection site samples were taken for histopathology, as well as blood samples for biochemical analysis. The results showed no histopathological changes, and the analyte values in biochemical tests remained within the reference range, suggesting the compound has a favorable safety profile.
No takes yet. Share an insight, caveat, or question.
Ibarra‐Velarde et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: